Login
$LGND
$306.75 -$2.04 (0.66%) Live

$LGND 8-K/A SEC Filings

Filed On Filing
02 Sep 2026 8-K/A: Financial Statements and Exhibits

The accompanying notes are an integral part of these condensed consolidated financial statements.

13 Nov 2023 8-K/A: Results of Operations and Financial Condition

SAN DIEGO, Calif. (November 8, 2023) – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. L...

10 Dec 2020 8-K/A: Financial Statements and Exhibits

We have audited the accompanying consolidated balance sheet of Pfenex Inc. and subsidiaries (the Company) as of

06 Dec 2018 8-K/A: Financial Statements and Exhibits
07 Mar 2018 8-K/A: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

On March 5, 2018, Ligand Pharmaceuticals Incorporated (the “Company” or “Ligand”) entered into a License Agreement with Roivant Sciences GmbH (“Roivant”), pursuant to which, among other things, Ligand granted to Roivant an exclusive (eve...

09 May 2016 8-K/A: Entry into a Material Definitive Agreement

This INTEREST PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of May 3, 2016, by and between CORMATRIX CARDIOVASCULAR, INC., a Georgia corporation (the “...

22 Mar 2016 8-K/A: Financial Statements and Exhibits

We have audited the accompanying combined financial statements of Open Monoclonal Technology, Inc. (a Delaware Corporation), OMT Therapeutics, Inc. (a Delaware Corporation), and OMT, LLC (a Delaware Limited Liability Company) (collective...

03 Mar 2016 8-K/A: Financial Statements and Exhibits

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

22 Jan 2013 8-K/A: Departure/Election of Directors or Officers; Compensation

On January 16, 2013, the Board of the Company approved base salary increases for 2013 and cash bonus payments for the 2012 fiscal year to be paid to the Company’s named executive officers. Under the Company’s bonus program, the target pe...

28 Sep 2011 8-K/A: Submission of Matters to a Vote of Security Holders

This Current Report on Form 8-K/A is being filed as an amendment to the Current Report on Form 8-K filed on June 3, 2011 by Ligand Pharmaceuticals Incorporated (the “Company”) in order to update information disclosed under “Item 5.07 Sub...

24 Jun 2011 8-K/A: Regulation FD Disclosure

The following presentation contains forward-looking statements regarding Ligand’s

12 Apr 2011 8-K/A: Completion of Acquisition or Disposition of Assets

Financial Statements and Report of Independent Certified Public Accountants

11 Apr 2011 8-K/A: Completion of Acquisition or Disposition of Assets

Financial Statements and Report of Independent Certified Public Accountants

25 Feb 2009 8-K/A: Financial Statements and Exhibits

The financial statements required by this Item with respect to the merger described in Item 2.01 in the Original 8-K, as modified hereby, were previously filed as part of Amendment No.1 to Registration Statement on Form S-4 filed by Liga...

25 Sep 2008 8-K/A: Entry into a Material Definitive Agreement; Regulation FD Disclosure

On September 24, 2008, Ligand entered into an Agreement and Plan of Merger (the “Merger Agreement”), with Pharmacopeia, Margaux Acquisition Corp, a direct wholly-owned subsidiary of the Company (“Merger Sub 1”) and Latour Acquisition, LL...

31 Aug 2004 8-K/A: Changes in Registrant's Certifying Accountant

Securities and Exchange Commission Mail Stop 11-3 450 5th Street, N.W. Washington, D.C. 20549

25 Aug 2004 8-K/A: Changes in Registrant's Certifying Accountant

Securities and Exchange Commission Mail Stop 11-3 450 5th Street, N.W.

25 Sep 1998 8-K/A: Financial Statements and Exhibits

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support